Please assess the completion status of the following clinical trial:

Trial Title: Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Patients with Philadelphia-Positive (Ph+) (or BCR/ABL+) accelerated phase chronic myeloid leukemia, Ph+ (or BCR/ABL+) blast phase chronic myeloid leukemia, or Ph+ (or BCR/ABL+) acute lymphoblastic leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate~* Men and women, 18 years of age or older~* Adequate hepatic function~* Adequate renal function~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized~* Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy~* Uncontrolled or significant cardiovascular disease~* Medications that increase bleeding risk~* Medications that change heart rhythms~* Dementia or altered mental status that would prohibit the understanding or rendering of informed consent~* History of significant bleeding disorder unrelated to CML~* Concurrent incurable malignancy other than CML~* Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy~* Prior therapy with BMS-35425~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dasatinib Twice a Day (BID) (Type: EXPERIMENTAL): 70 mg dasatinib twice a day (BID)
- dasatinib Once a Day (QD) (Type: EXPERIMENTAL): 140 mg dasatinib once a day (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).